scholarly journals Lipoxygenases, Hyaluronidase, and Xanthine Oxidase Inhibitory Effects Extracted from Five Hydrocotyle Species

2021 ◽  
Vol 27 (4) ◽  
pp. 277-282
Author(s):  
Seok Hyeon Moon ◽  
Yong Lim ◽  
Man Kyu Huh
2017 ◽  
Vol 19 ◽  
pp. 39-45 ◽  
Author(s):  
Lu Qu ◽  
Jing-Ya Ruan ◽  
Li-Jun Jin ◽  
Wen-Zhong Shi ◽  
Xiao-Xia Li ◽  
...  

2020 ◽  
Vol 36 ◽  
pp. 162-165
Author(s):  
Cheng-mei Xiao ◽  
Xian-hui Jia ◽  
Hong-fang Du ◽  
Huan-xin Zhao ◽  
Cheng-lin Du ◽  
...  

Biomolecules ◽  
2019 ◽  
Vol 9 (11) ◽  
pp. 655 ◽  
Author(s):  
Fliszár-Nyúl ◽  
Mohos ◽  
Bencsik ◽  
Lemli ◽  
Kunsági-Máté ◽  
...  

7,8-dihydroxyflavone (DHF) is a flavone aglycone which has beneficial effects in several central nervous system diseases. Most of the pharmacokinetic properties of DHF have been characterized, while only limited information is available regarding its interactions with serum albumin and biotransformation enzymes. In this study, the interactions of DHF with albumin was examined employing fluorescence spectroscopy and ultrafiltration. Furthermore, the inhibitory effects of DHF on cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) and xanthine oxidase (XO) enzymes were also tested using in vitro models. Our results demonstrate that DHF forms a stable complex with albumin (K = 4.9 × 105 L/mol) and that it is able to displace both Site I and Site II ligands. Moreover, DHF proved to be a potent inhibitor of each enzyme tested, showing similar or slightly weaker effects than the positive controls used. Considering the above-listed observations, the coadministration of DHF with drugs may interfere with the drug therapy due to the development of pharmacokinetic interactions.


2019 ◽  
Vol 20 (11) ◽  
pp. 2681 ◽  
Author(s):  
Violetta Mohos ◽  
Attila Pánovics ◽  
Eszter Fliszár-Nyúl ◽  
Gabriella Schilli ◽  
Csaba Hetényi ◽  
...  

Quercetin is an abundant flavonoid in nature and is used in several dietary supplements. Although quercetin is extensively metabolized by human enzymes and the colonic microflora, we have only few data regarding the pharmacokinetic interactions of its metabolites. Therefore, we investigated the interaction of human and microbial metabolites of quercetin with the xanthine oxidase enzyme. Inhibitory effects of five conjugates and 23 microbial metabolites were examined with 6-mercaptopurine and xanthine substrates (both at 5 μM), employing allopurinol as a positive control. Quercetin-3′-sulfate, isorhamnetin, tamarixetin, and pyrogallol proved to be strong inhibitors of xanthine oxidase. Sulfate and methyl conjugates were similarly strong inhibitors of both 6-mercaptopurine and xanthine oxidations (IC50 = 0.2–0.7 μM); however, pyrogallol inhibited xanthine oxidation (IC50 = 1.8 μM) with higher potency vs. 6-MP oxidation (IC50 = 10.1 μM). Sulfate and methyl conjugates were approximately ten-fold stronger inhibitors (IC50 = 0.2–0.6 μM) of 6-mercaptopurine oxidation than allopurinol (IC50 = 7.0 μM), and induced more potent inhibition compared to quercetin (IC50 = 1.4 μM). These observations highlight that some quercetin metabolites can exert similar or even a stronger inhibitory effect on xanthine oxidase than the parent compound, which may lead to the development of quercetin–drug interactions (e.g., with 6-mercaptopurin or azathioprine).


2015 ◽  
Vol 166 ◽  
pp. 270-274 ◽  
Author(s):  
Noriyoshi Masuoka ◽  
Ken-ichi Nihei ◽  
Ayami Maeta ◽  
Yoshiro Yamagiwa ◽  
Isao Kubo

Sign in / Sign up

Export Citation Format

Share Document